In parallel of its drug candidate pharmaceutical development, CORAL BIOME masters exclusive access to biomass through clonal reproduction by high-tech in-house aquaculture of fully phylogenetically characterized coral species. This aquaculture supplies our R&D operations with a diversified and controlled biomass of a hundred different coral species, and thus guarantees high quality industrial production.
We seeks to license our drug candidate to pharmaceutical partners, who will have the capacity to conduct the last development phases and bring the drug to market.
We will capitalize on our expertise by supplying our partners with quality-controlled biomass. Indeed, production of reproducible pharmaceutical grade coral biomass requires specific authorizations, appropriate technical resources and know-how. We fully mastered these specifics that are absent from pharmaceutical industries and standard aquaculture farms.